$5.62
0.88% yesterday
Nasdaq, Sep 03, 10:00 pm CET
ISIN
US2210151005
Symbol
CRVS

Corvus Pharmaceuticals, Inc. Stock price

$5.62
+1.31 30.39% 1M
+1.67 42.28% 6M
+0.27 5.05% YTD
+1.58 39.11% 1Y
+4.71 518.94% 3Y
+2.32 70.30% 5Y
-8.63 60.56% 10Y
-8.63 60.56% 20Y
Nasdaq, Closing price Wed, Sep 03 2025
-0.05 0.88%
ISIN
US2210151005
Symbol
CRVS
Industry

Key metrics

Basic
Market capitalization
$418.8m
Enterprise Value
$344.4m
Net debt
positive
Cash
$74.4m
Shares outstanding
74.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
5.2
Financial Health
Equity Ratio
47.3%
Return on Equity
-191.3%
ROCE
-43.9%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-35.5m | -
EBIT
$-35.5m | $-42.7m
Net Income
$-45.1m | $-31.2m
Free Cash Flow
$-29.0m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-52.2% | -
EBIT
-51.9% | -55.1%
Net Income
-99.6% | 49.9%
Free Cash Flow
-36.4%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-0.6
FCF per Share
$-0.4
Short interest
15.8%
Employees
31
Rev per Employee
$0.0
Show more

Is Corvus Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Corvus Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Corvus Pharmaceuticals, Inc. forecast:

11x Buy
92%
1x Hold
8%

Analyst Opinions

12 Analysts have issued a Corvus Pharmaceuticals, Inc. forecast:

Buy
92%
Hold
8%

Financial data from Corvus Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 9.02 9.02
24% 24%
-
- Research and Development Expense 27 27
64% 64%
-
-35 -35
52% 52%
-
- Depreciation and Amortization 0.09 0.09
18% 18%
-
EBIT (Operating Income) EBIT -36 -36
52% 52%
-
Net Profit -45 -45
100% 100%
-

In millions USD.

Don't miss a Thing! We will send you all news about Corvus Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Corvus Pharmaceuticals, Inc. Stock News

Positive
Seeking Alpha
22 days ago
Company's soquelitinib shows promising phase 1 results in moderate-to-severe atopic dermatitis, with key phase 1 and phase 2 catalysts expected before the end of 2025. The drug's versatility targets both cancer and autoimmune disorders, expanding its market potential beyond oncology into other large market indications. Financial runway is limited to Q4 2026, with potential dilution risk if addi...
Neutral
Seeking Alpha
27 days ago
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Leiv Lea - Chief Financial Officer Richard A. Miller - Co-Founder, President, CEO & Chairman of the Board Conference Call Participants Aydin Huseynov - Ladenburg Thalmann & Co. Inc., Research Division Jeffrey Michael Jones - Oppenheimer & Co. Inc., Research Division Zack K...
Positive
The Motley Fool
28 days ago
Corvus (CRVS) Q2 Loss Beats Estimates
More Corvus Pharmaceuticals, Inc. News

Company Profile

Corvus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of oncology therapies. The company focuses on disabling cancer's ability to subvert immune attack by inhibiting adenosine in the tumor microenvironment and by blocking its production by tumors. Its product pipeline includes Adenosine A2A Receptor Antagonist CPI-444, Adenosine Production Inhibitor Anti-CD73, Adenosine A2B Receptor Antagonist, ITK Inhibitor, and Myeloid Cell Suppression. The company was founded by Richard A. Miller, Peter A. Thompson, and Joseph J. Buggy on January 27, 2014 and is headquartered in Burlingame, CA.

Head office United States
CEO Richard Miller
Employees 31
Founded 2014
Website www.corvuspharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today